Injectable HIV treatment, prevention: Everything you need to know
So much has changed when it comes to injectables — get some clarity here.
March 26 2024 3:28 PM
By continuing to use our site, you agree to our Private Policy and Terms of Use.
So much has changed when it comes to injectables — get some clarity here.
A recent study shows significance increase in awareness and use of PrEP among at-risk men, but more work needs to be done.
New HIV transmission rates are down in the African country, but does it make up for Madiba's early missteps?
The data confirmed what the science has maintained at the #AIDS2018 conference in Amsterdam today.
David Cooper played a crucial role in developing the drug trials for many of the HIV medications currently on the market and saving lives today.
UCLA has developed an intervention program called LINK LA that connects ex-inmates to continuous healthcare once they are out of jail and helps them maintain their viral suppression in the outside world.
Despite data showing a man became HIV-positive while practicing PrEP, researchers have a theory that he became poz after stopping PrEP.
The once-daily regimen for those with HIV can now be prescribed to those with a common treatment resistance.
Transmission rates of HIV are still highest among gay and bi men.
The new drugs are welcome alternatives to those starting an antiretroviral treatment.
The Campbell Foundation bestows large grant to Stanford researchers to continue developing an HIV drug resistance test.
The latest FDA approved HIV medication is a single regimen option for those beginning treatment.
Get a close look at the new treatment options for 2018.
The FDA has approved a years-in-development treatment for multidrug-resistant HIV, a boon for those who've become resistant to most or all available HIV meds.
An HIV policy survey was sent by the ACT Now: End AIDS Coalition to all major presidential candidates. Here's one response.
Promising new research thrusts HIV vaccines into the spotlight.
Researchers believe the drug could work much longer than daily antiretrovirals or PrEP.
Scientists discover a new way to deliver HIV meds via a once-a-week capsule, and it just might change the world.
Researchers from New York’s Aaron Diamond AIDS Research Center presented a new long-lasting PrEP pill at the 25th Conference on Retroviruses and Opportunistic Infections (CROI).
A controversial case has launched a state investigation of discriminatory and unethical insurance practices.